Tonix Pharmaceuticals Holding Corp. - 8-K Filing
Tonix Pharmaceuticals reported first-quarter operational metrics showing 2,145 unique healthcare providers prescribed TONMYA, with 3,588 patients initiating treatment and ~5,400 prescriptions filled. The company secured a managed care partnership providing access to approximately 35 million U.S. commercial lives for TONMYA and plans an adaptive Phase 2 field study for TNX-4800 in the prevention of Lyme disease by mid-2027 pending FDA agreement.
Tickers: $TNXP